Haleon plc (HLN)

Barclays has repeated its 'overweight' call and 430p price target for Haleon PLC (LSE:HLN, NYSE:HLN) following a solid set of second-quarter results. In a note issued on Friday, it noted that the consumer health group continues to deliver organic revenue growth ahead of expectations.

Haleon plc (NYSE:HLN ) Q2 2025 Earnings Q&A Conference July 31, 2025 4:30 AM ET Company Participants Brian James McNamara - CEO & Executive Director Dawn Amanda Allen - CFO & Director Jo Russell - Head, IR Conference Call Participants Callum Elliott - Sanford C. Bernstein & Co., LLC.

Brian McNamara​​, chief executive of of Haleon said the company is "quite optimistic about emerging market growth," whilst still developing a "great" business in developed markets.

British consumer healthcare company Haleon lowered its annual organic revenue growth forecast to 3.5% on Thursday, citing weaker performance in the United States.

Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?

Haleon PLC Sponsored ADR (HLN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

LONDON--(BUSINESS WIRE)-- #Groundbreaking--This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility will enhance Haleon's science capabilities, accelerate innovation, and serve as a centre of excellence for global oral health research. The groundbreaking ceremony, attended by UK Minister Baroness Jones, marks an important step in Ha.

LONDON , June 24, 2025 /PRNewswire/ -- Haleon (LSE: HLN) (NYSE: HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025.

Sensodyne launches new premium Clinical White toothpaste to brighten Canadians' smiles in time for National Smile Day. Sensodyne launches new premium Clinical White toothpaste to brighten Canadians' smiles in time for National Smile Day.

Haleon plc (NYSE:HLN ) Q1 2025 Results Conference Call April 30, 2025 3:30 PM ET Company Participants Jo Russell - Head-Investor Relations Dawn Allen - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Rashad Kawan - Morgan Stanley David Hayes - Jefferies Warren Ackerman - Barclays Celine Pannuti - JP Morgan Tom Sykes - Deutsche Bank Edward Lewis - Redburn Atlantic Victoria Petrova - Bank of America Jeremy Fialko - HSBC Karel Zoete - Kepler Jo Russell Good morning, everyone, and welcome to conference call for our first quarter trading statement. I'm Jo Russell, Head of Investor Relations.

Haleon on Thursday raised its medium-term target for profit growth from 2026, banking on strength in key markets and costs cuts within its supply chain, which would save the consumer healthcare group 800 million pounds ($1.07 billion) in the next five years.

Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 1% after the toothpaste and painkillers maker reported slightly stronger first-quarter growth than expected but saw a weaker performance than expected from its vitamins, minerals and supplements (VMS) arm in America.  The FTSE 100 group posted a Q1 update showing 3.5% organic revenue growth, supported by positive contributions from all product categories and regions, beating an average City forecast of 3.3%.

British consumer healthcare group Haleon on Wednesday reported a 2.3% fall in its first-quarter revenue as sluggish demand for its cold and cough medicines outside of North America continued to weigh.

British consumer healthcare group Haleon said on Tuesday it has gained complete ownership of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake for about 1.62 billion yuan ($221.4 million).

Citi believes Haleon PLC (LSE:HLN, NYSE:HLN) is well positioned for the current uncertain climate, describing the consumer healthcare group as a solid defensive play for investors concerned about recession risks and the fallout from Donald Trump's new tariff regime. Shares in the maker of household brands such as Sensodyne and Panadol, have been under pressure amid broader worries over US consumer demand and a tough comparison with last year's strong flu season.

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding margins and further debt reduction on a net debt/adjusted EBITDA basis (now 2.8x from 4.0x) demonstrate financial strength in uncertain economic conditions. Robust dividend coverage (2.5x covered by earnings) with steady growth and the strategic streamlining of its portfolio highlights Haleon as a reliable defensive investment.